Strains, composition and method of use
The present invention relates to a bacterial strain having a genetic homology of at least 95% to one or more of the bacterial strains selected from the group consisting of: Weissella viridescens LB10G, which is deposited as DSM 32906; Lactobacillus paracasei LB113R, which is deposited as DSM 32907; Lactobacillus plantarum LB244R, which is deposited as DSM 32996; Lactobacillus paracasei LB116R, which is deposited as DSM 32908; Enterococcus faecium LB276R, which is deposited as DSM 32997; Lactobacillus plantarum LB316R, which is deposited as DSM 33091; Leuconostoc mesenteriodes LB341R; Leuconostoc mesenteriodes LB349R, which is deposited as DSM 33093; Lactobacillus plantarum LB356R, which is deposited as DSM 33094; Lactobacillus plantarum LB312R, which is deposited as DSM 33098.
1. A bacterial strain capable of treating, alleviating, suppressing, prophylaxis, and/or preventing growth of a pathogenic micro-organism wherein the one or more bacterial strain is Lactobacillus plantarum LB356R, which is deposited as DSM 33094 or Lactobacillus plantarum LB244R, which is deposited as DSM 32996, and wherein the one or more bacterial strains is provided as one or more viable strains, one or more dead or inactivated strains, one or more strain lysate: one or more strain metabolites or a combination hereof, or wherein the viable bacterial strain is provided in an encapsulated, micro-encapsulated, spray-dried and/or lyophilized form.
2. The bacterial strain according to claim 1 , wherein the growth of Staphylococcus aureus in co-culture is reduced by at least 20%.
3. The bacterial strain according to claim 1 , wherein the bacterial strain is an isolated bacterial strain.
4. A composition comprising one or more of the bacterial strains according to claim 1 .
5. The composition according to claim 4 , wherein the composition is formulated into an emulsion; an oil; a gum; a paste; a powder, a talc; a lotion; a custard; a foam; a créme; a gel; an ointment; a suspension; a mist; or a liquid.
6. The composition according to claim 4 , wherein the composition is a topical composition, an oral composition or a rectal composition.
7. The composition according to claim 4 , wherein the concentration of the bacterial strain is in the range of 10 3 to 10 14 colony forming units (CFU).
8. The composition according to claim 4 , wherein the concentration of the bacterial strain is in a concentration of 0.001% (w/w) to 20% (w/w).
9. The composition according to claim 4 , wherein the composition further comprises a prebiotic composition.
10. The composition according to claim 4 , wherein the one or more bacterial strain are the only bacteria present in the composition.
11. The composition according to claim 4 , for treating; alleviating, suppressing; prophylaxis; and/or preventing growth of a pathogenic micro-organism.
12. A method for treatment; alleviation; suppression; and/or the prophylaxis of one or more pathogenic bacterial infections or antibiotic resistant bacterial infections in a mammal, comprising administration of the composition according to claim 4 .
13. The method according to claim 12 , wherein bacterial infection is a Staphylococcus infection in a mammal.
14. The method according to claim 13 , wherein the Staphylococcus infection is an MRSA-infection.
15. The method according to claim 12 , for the treatment; alleviation; suppression; and/or the prophylaxis of diseases resulting from Staphylococcus infections.